Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Ocular Therapeutix, Inc. on June 11, 2019. The company is an emerging growth company incorporated in Delaware, with its common stock (OCUL) trading on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes
No material financial changes or operational updates are disclosed in this filing. The document serves to disclose the outcomes of shareholder votes regarding director elections and auditor ratification.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, management commentary, risks, contingencies, or unusual items. It strictly details the procedural results of the annual meeting.
Investor Verification Checklist
- Director Elections: Verify the election of Seung Suh Hong, Ph.D., Richard L. Lindstrom, M.D., and Leslie J. Williams as Class II directors serving until 2022.
- Voting Results: Note that Richard L. Lindstrom, M.D. received a significant number of withheld votes (2,789,660) compared to the other nominees.
- Auditor Ratification: Confirm the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Broker Non-Votes: Observe that 18,261,946 shares were recorded as broker non-votes for the director elections.